Not just a telling story...
Click the image to read the full article
OLON SPA (P&R Group) ACQUIRES RICERCA BIOSCIENCES CHEMICAL DIVISION IN OHIO (USA)
Acquisition strengthens service offering of global CDMO and Generics provider for research and manufacturing
Milan (Italy) – June 9, 2017 Olon S.p.A., a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) and Generics supplier, announced today the acquisition of Ricerca Biosciences’ Chemical Division of the contract research (CRO) and CDMO based in Concord, Ohio, USA. This acquisition strengthens the service offering of Olon for the pharmaceutical and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.
Paolo Tubertini, CEO of Olon, commented, "By acquiring a research and manufacturing base in the US, Olon will have the opportunity to accelerate growth by adding new CDMO projects and to develop new Generic products for the American market." Luca Mantovani, OLON Managing Board member, added, "We are delighted to add Ricerca Biosciences to Olon Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers". No financial details were disclosed.
Ricerca Biosciences is a US-based CRO supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution. Ricerca’s extensive process/synthetic chemistry, analytical chemistry and engineering expertise provides a synergy that excels at first-time scale-ups and subsequent development of safe, reliable, robust and cost effective manufacturing processes. Meeting client needs has been the foundation of Ricerca’s business philosophy and is second only to its commitment to safety and regulatory compliance. www.ricerca.com